PMID- 37811811
OWN - NLM
STAT- MEDLINE
DCOM- 20240102
LR  - 20240322
IS  - 1440-1711 (Electronic)
IS  - 0818-9641 (Print)
IS  - 0818-9641 (Linking)
VI  - 102
IP  - 1
DP  - 2024 Jan
TI  - Molecular insights into the HLA-B35 molecules' classification associated with HIV 
      control.
PG  - 34-45
LID - 10.1111/imcb.12698 [doi]
AB  - Human leukocyte antigen (HLA) class I molecules have been shown to influence the 
      immune response to HIV infection and acquired immunodeficiency syndrome 
      progression. Polymorphisms within the HLA-B35 molecules divide the family into 
      two groups, namely, Px and PY. The Px group is associated with deleterious 
      effects and accelerated disease progression in HIV(+) patients, whereas the PY 
      group is not. The classification is based on the preferential binding of a 
      tyrosine at the C-terminal part of the peptide in the PY group, and a nontyrosine 
      residue in the Px group. However, there is a lack of knowledge on the molecular 
      differences between the two groups. Here, we have investigated three HLA-B35 
      molecules, namely, HLA-B*35:01 (PY), HLA-B*35:03 (Px) and HLA-B*35:05 
      (unclassified). We selected an HIV-derived peptide, NY9, and demonstrated that it 
      can trigger a polyfunctional CD8(+) T-cell response in HLA-B*35:01(+) /HIV(+) 
      patients. We determined that in the complex with the NY9 peptide, the PY molecule 
      was more stable than the Px molecule. We solved the crystal structures of the 
      three HLA molecules in complex with the NY9 peptide, and structural similarities 
      with HLA-B*35:01 would classify the HLA-B*35:05 within the PY group. 
      Interestingly, we found that HLA-B*35:05 can also bind a small molecule in its 
      cleft, suggesting that small drugs could bind as well.
CI  - (c) 2023 The Authors. Immunology & Cell Biology published by John Wiley & Sons 
      Australia, Ltd on behalf of the Australian and New Zealand Society for 
      Immunology, Inc.
FAU - Lobos, Christian A
AU  - Lobos CA
AD  - Department of Biochemistry and Chemistry, La Trobe Institute for Molecular 
      Science, La Trobe University, Bundoora, VIC, Australia.
AD  - Department of Biochemistry and Molecular Biology, Monash University, Clayton, 
      VIC, Australia.
FAU - Chatzileontiadou, Demetra Sm
AU  - Chatzileontiadou DS
AD  - Department of Biochemistry and Chemistry, La Trobe Institute for Molecular 
      Science, La Trobe University, Bundoora, VIC, Australia.
AD  - Department of Biochemistry and Molecular Biology, Monash University, Clayton, 
      VIC, Australia.
FAU - Sok, Bonin
AU  - Sok B
AD  - Department of Biochemistry and Chemistry, La Trobe Institute for Molecular 
      Science, La Trobe University, Bundoora, VIC, Australia.
FAU - Almedia, Coral-Ann
AU  - Almedia CA
AD  - Department of Clinical Immunology and PathWest, Fiona Stanley Hospital, Perth, 
      WA, Australia.
AD  - School of Medicine, University of Western Australia, Perth, WA, Australia.
FAU - Halim, Hanim
AU  - Halim H
AD  - Department of Biochemistry and Molecular Biology, Monash University, Clayton, 
      VIC, Australia.
FAU - D'Orsogna, Lloyd
AU  - D'Orsogna L
AD  - Department of Clinical Immunology and PathWest, Fiona Stanley Hospital, Perth, 
      WA, Australia.
AD  - School of Medicine, University of Western Australia, Perth, WA, Australia.
FAU - Gras, Stephanie
AU  - Gras S
AUID- ORCID: 0000-0001-7416-038X
AD  - Department of Biochemistry and Chemistry, La Trobe Institute for Molecular 
      Science, La Trobe University, Bundoora, VIC, Australia.
AD  - Department of Biochemistry and Molecular Biology, Monash University, Clayton, 
      VIC, Australia.
LA  - eng
GR  - Australian Institute of Nuclear Science and Engineering/
GR  - 1159272/National Health and Medical Research Council/
PT  - Journal Article
DEP - 20231009
PL  - United States
TA  - Immunol Cell Biol
JT  - Immunology and cell biology
JID - 8706300
RN  - 0 (HLA-B35 Antigen)
RN  - 0 (HLA-B Antigens)
RN  - 0 (Peptides)
SB  - IM
MH  - Humans
MH  - *HIV Infections
MH  - HLA-B35 Antigen/chemistry
MH  - *HIV-1
MH  - HLA-B Antigens
MH  - Peptides
PMC - PMC10952751
OTO - NOTNLM
OT  - CD8+ T cell
OT  - HIV
OT  - HLA
OT  - immune response
OT  - peptide presentation
COIS- The authors declare no competing interests.
EDAT- 2023/10/09 12:43
MHDA- 2024/01/02 11:44
PMCR- 2024/03/20
CRDT- 2023/10/09 07:43
PHST- 2023/07/04 00:00 [revised]
PHST- 2023/09/16 00:00 [revised]
PHST- 2022/10/14 00:00 [received]
PHST- 2023/09/19 00:00 [accepted]
PHST- 2024/01/02 11:44 [medline]
PHST- 2023/10/09 12:43 [pubmed]
PHST- 2023/10/09 07:43 [entrez]
PHST- 2024/03/20 00:00 [pmc-release]
AID - IMCB12698 [pii]
AID - 10.1111/imcb.12698 [doi]
PST - ppublish
SO  - Immunol Cell Biol. 2024 Jan;102(1):34-45. doi: 10.1111/imcb.12698. Epub 2023 Oct 
      9.